A Conversation About the ASCEND Clinical Trial with Dr. Karl Kieburtz скачать в хорошем качестве

A Conversation About the ASCEND Clinical Trial with Dr. Karl Kieburtz

This content is made possible by the generous support of viewers and listeners like you. If you would like to make a donation, please visit: https://dpf.org/youtubedonation In this video, Davis Phinney Foundation Executive Director, Polly Dawkins, talks with Karl Kieburtz, MD, MPH, about the ASCEND clinical trial. This trial explores a new medication called CVN424, which takes a novel approach to treating Parkinson’s symptoms. Watch the video to learn about CVN424 and the ASCEND clinical trial exploring its use as a monotherapy for people with Parkinson’s. CVN424 has been developed by Cerevance, who, in collaboration with Rho, sponsored the production of this video. More information about the ASCEND trial is available at https://ascendclinicaltrial.com/. To be notified of more videos like this, subscribe to our YouTube channel here:    / davisphinneyfdn   -- 0:00 - Introduction 2:17 - Start of discussion 2:46 - What is the medicine CVN424? 4:46 - How was CVN424 discovered? 8:36 - Is the goal for CVN424 symptom modifying or symptom relief? 9:56 - What research has been done to get CVN424 to this point? 12:32 - What is mono-therapy? 15:00 - What is the new phase of the trial measuring? 16:59 - How is the trial structured? 19:58 - Who is eligible for this trial? 23:11 - How can people find more information about joining the trial? 25:30 - What are the benefits of joining the trial? 27:19 - How long will it take for the medication to come to market, if it is approved? 29:05 - How is this medication different from Levodopa and why would that be a benefit? 33:19 - Is there a relationship between CVN424 and deep brain stimulation (DBS)? 35:32 - What excites you about this particular therapy? 38:01 - Conclusion